Objective: To compare the safety and efficacy of transcathether aortic valve-in-valve implantation (ViV-TAVI) in degenerated stentless bioprostheses with failed stented valves and degenerated native aortic valves.
Results: Patients with degenerated stentless valves were younger (65.6, CI 58-73.1 years vs 75.6, CI 72. [stented] vs 80.1, CI 78.7-81.6 y.
[native], P < 0.001).
Implantation was required later after surgery (11.5, CI 8-14.9 years) in the stentless cohort as compared with the stented one (6.2, CI 4.7-7.6 years, P = 0.006). ViV-TAVI in the stentless group was also associated with larger amount of contrast (211, CI 157-266 mL vs 135, CI 104-167 mL [stented] vs 132 (119-145) mL [native], P = 0.022). Using VARC-2 composite endpoints, ViV-TAVI in stentless prostheses was characterized by a lower device success (50% vs 76% in stented vs 88.9% in native TAVI, P < 0.001), but comparable early safety up to 30 days (73.7% vs 84% vs 81.8%, respectively, log-rank P = 0.667) and long-term clinical efficacy beyond 30 days (72.2% vs 72% vs 73.8%, respectively, log-rank P = 0.963).
Conclusions: Despite technical challenges and a lower device success, ViV-TAVI in stentless aortic bioprostheses achieves similar safety, efficacy, and functional improvement as in stented or degenerated native valves.
K E Y W O R D S
aortic valve insufficiency, aortic valve stenosis, heart valve diseases, surgical valve
| INTRODUCTION
For almost a decade, transcatheter valve-in-valve implantation (ViV-TAVI) has been an important off-label application for the rapidly growing field of transcathether aortic valve implantation (TAVI). 1 In 2015, following several observational data analyses-ViV-TAVI gained definitive recognition as a feasible and beneficial procedure in patients with failed surgically implanted bioprosthetic valves and was approved by the Food and Drug Administration as an extended indication for the two most popular, self-and balloon-expandable, systems. 2 Rapid worldwide growth in the number of TAVI procedures is accompanied by the natural transition to lower risk populations and, collaterally, patients with severe aortic stenosis treated surgically are becoming younger. Moreover, in the last years a substantial shift away from mechanical heart valves has occurred and bioprosthetic valves have claimed majority of market share, irrespectively of patients' age. 3 Thus, we may expect that the population, potentially requiring ViV-TAVI in the upcoming years, will grow significantly. It is therefore crucial to best describe and analyze currently treated cohorts undergoing ViV-TAVI in order to better understand any potential limitations of this method, especially in reference to different types of surgical aortic bioprosthesis implanted. The design of surgically implanted stentless valve prostheses is intended to achieve a more physiological flow pattern and superior hemodynamics in comparison to stented valves. was assessed with a log-rank test with Kaplan-Meier curves. All the tests were two-tailed and a significance level of P < 0.05 was used.
Analysis was processed using the SPSS software, version 23 (IBM Statistics, New York). 6.2, CI 4.7-7.6 years, P = 0.006). Table 2 contains detailed data on SAVR.
Regurgitation was a more frequent mechanism behind prosthesis failure and the mean label size of implanted TAVI prosthesis was significantly larger in stentless cohort as compared with stented one.
Moreover, ViV-TAVI in the stentless group was associated with (Table 3 ) For the native TAVI cohort, stenosis was more frequently an indication for the procedure with higher utilization of pre-and postdilatation (Table 3) .
| Echocardiographic data
At baseline, patients with failed stentless bioprostheses had lower mean left ventricular ejection fraction as compared with the stented cohort and the native TAVI. This difference was maintained also after the procedure, at discharge and at followup. Pre-procedural aortic valve areas (AVA) as well as indexed AVA were larger in stentless cohort as compared with remaining patients. The baseline mean and maximal transvalvular gradients were lower in all valve-in-valve patients (irrespective of stentless or stented valves), as opposed to the native TAVI. There was a gradual increase in at least moderate grade regurgitation, lowest in native and highest in stentless patients (Table 4) . At follow-up those that underwent TAVI, due to native valve degeneration, were characterized by larger AVA and indexed AVA and lower transvalvular gradients (Table 4) . 
| Clinical outcomes
VARC-2 defined device success achieved in stentless cohort was 50%, which showed significant underperformance in relation to the remaining groups (76% in stented vs 89% in native TAVI, P < 0.001) (Figure 1 ). The necessity for implantation of more than one prosthesis (15%) and absence of intended performance mainly due to elevated transvalvular gradients (20%) and moderate paravalvular leak (10%)
were major factors decreasing device success rate in those patients.
Lack of device success in stented and native cohorts was driven almost only by insufficient performance of the implanted valve (Table 5 ). In terms of 30 days performance, defined by VARC-2 as early safety, the results were comparable between all groups (73.7% vs 84% vs 81.8%, respectively, log-rank P = 0.667). (Figure 2 ) Early safety in the stentless group was impaired mainly due to the occurrence of acute kidney injury (16%) and one case of coronary obstruction (5%) ( Table 5 ).
Clinical efficacy in the stentless cohort (72%) also corresponded well with stented and native cohorts (72% vs 73.8%, respectively, log-rank P = 0.963) (Figure 3) . Finally, the frequency of good functional status 
| DISCUSSION
The main finding of the present study is that ViV-TAVI in patients with failed stentless valves, despite being more technically complex and demanding, allows achieving comparable clinical results with interventions in stented surgical or native valves. Procedure-wise, the necessity for overcoming anatomical difficulties to position the prosthesis correctly translates into lower device success, but also is more time consuming and requires greater volumes of contrast, which may subsequently be associated with higher incidence of acute kidney injury. Two years after the first-in-man ViV-TAVI, the first application of the procedure was described in a patient with a failed stentless valve. 8, 9 Almost a decade later, while general performance of ViV-TAVI has been assessed, the literature is still lacking in comprehensive evaluation of this patient subset, with only a handful of case reports. 10, 11 To the best of our knowledge, this is the first study confronting directly ViV-TAVI in patients with stentless valves to those with stented and native valves.
Feasibility and acceptable outcomes of ViV-TAVI in comparison to
re-do SAVR were reported previously in a group of 27 patients with failing surgical aortic stentless valves. 12 Duncan et al 13 provided
reassuring data on the performance of ViV-TAVI in a group of 22 patients with homografts mostly and Bapat et al 14 described rather favourable results in 10 patients with failed stenltess valves treated only with the use of balloon-expandable prostheses. In contrast, small case series of ViV-TAVI in specifically designed supra-anullar surgical prosthesis (Freedom Solo) showed high risk of coronary occlusion. 15 The current study complements the above-mentioned results in various aspects. First, we compared patients undergoing TAVI, divided accordingly to the type of failed surgical valve and a propensitymatched native TAVI cohort. Second, we enrolled more diversified stentless prostheses cohort, also including important subgroup with homografts, whereas previously studied population consists either of specific xenografts or homografts. Finally, we decided to use composite endpoints, believing they are more transparent indicators of outcomes in small populations than multiple single events considered separately.
Correct positioning of the prosthesis during ViV-TAVI with the stentless valves is made challenging by the lack of a sewing ring, which otherwise would assure both anchoring and easier guidance through radio-opaque markers. Additionally, sewing technique of some stentless valves may increase the risk of coronary obstruction after a TAVI prosthesis is deployed. In our sample, the need for a second prosthesis (incorrect positioning by VARC-2) in stentless group involved only patients with homografts with no detectable calcifications treated for pure aortic regurgitation. In two cases CoreValve was deployed too deep into the left ventricle leading to a significant paravalvular leak and in the 3rd case CoreValve Evolut R prosthesis was implanted too high and embolized to ascending aorta.
It seems that the above-mentioned obstacles can be avoided with the application of fully repositionable prostheses, allowing final 
| Study limiatations
First, the major limitation of the present study is a relatively small series of patients included, which, in consequence, may restrict statistical FIGURE 1 Device success rate in respective groups. Device success defined according to VARC-2 as a composite of: (1) absence of procedural mortality; (2) correct positioning of a single prosthetic heart valve into the proper anatomical location; and (3) intended performance of the prosthetic heart valve (no patient-prosthesis mismatch, mean transvalvular gradient <20 mmHg, peak velocity <3 m/s, and no moderate or severe prosthetic valve regurgitation). Device success was 50% in stenless ViV-TAVI, 76% in stented ViV-TAVI and 88.9% in native TAVI (P < 0.001) power to detect significant differences. Nevertheless, this is one of the larger data sets on this patient population. Second, although not statistically significant, the majority of ViV-TAVI cases in stentless cohort were performed with 1st generation prostheses with limited repositionability functions and this could have influenced lower device success in this group. Nonetheless, two out of four cases with the need for more than one bioprosthesis during ViV-TAVI (three in stentless and one in stented cohorts) occurred with 2nd generation devices.
Third, patients in the stentless group were significantly younger, which seems to be characteristic for this subset of patients and could not be corrected by propensity score matching-thus potentially influencing long-term clinical follow-up. Finally, procedural success rate in ViV-TAVI was assessed using strict VARC-2 definitions. Probably, for future analysis in ViV populations, procedural efficacy could be estimated better on a case by case basis, where significant (but not exactly fulfilling strict criteria developed for native TAVI) reduction of baseline regurgitation or stenosis on failed surgical prosthesis could be considered as a success.
| CONCLUSION
In conclusion, valve-in-valve TAVI for failed stentless surgical prostheses can be performed with good early-and mid-term clinical results that are comparable with those performed on patients with stented surgical or degenerated native valves and provide immediate hemodynamic improvement of high-risk patients. However, it is important to understand current pitfalls of the procedure in order to minimize subsequent adverse outcomes following improper positioning of a prosthesis. A presumption can be made that fully repositionable and preferably easily retrievable devices might be best suited for the described conditions. Further investigations should be encouraged to gain more insight into the subject.
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